Stocks Health care ELTP
OTC · Health careElite Pharmaceuticals Inc (ELTP)
Elite Pharmaceuticals Inc brought in $141M of revenue over the twelve months to June 30, 2026, up 33.7% from a year earlier. Net income was $56.7M, a net margin of 40.2%. Operating cash flow minus capital spending left $22.8M of free cash flow in fiscal 2026. At June 30, 2026 it held $39.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Watch ELTP in 60 secondsWhat Elite Pharmaceuticals Inc does
Elite Pharmaceuticals Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker ELTP.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2026 | $148.9M | $44.9M | $0.03 | $22.8M |
| 2025 | $84M | -$4.3M | $0.00 | $5.8M |
| 2024 | $56.6M | $20.1M | $0.02 | -$4M |
| 2023 | $34.2M | $3.6M | $0.00 | -$2.4M |
| 2022 | $32.3M | $8.9M | $0.01 | $6M |
| 2021 | $25.4M | $5.1M | $0.00 | n/a |
Full financial statements: income, balance sheet and cash flow
Where ELTP ranks in Health care
Latest SEC filings
What Elite Pharmaceuticals Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 13, 2026
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 20% to $32.4M versus the same quarter last year; diluted EPS $0.01 versus -$0.01.
- August 11, 2026Investor disclosure 8-K/A
- August 10, 2026
- August 4, 2026
- June 29, 2026
- June 29, 2026Annual report 10-K · period to March 31, 2026Revenue rose 77% to $148.9M versus the prior year; diluted EPS $0.03 versus $0.00.
- June 23, 2026
- June 15, 2026
- June 1, 2026
What is ELTP worth? A DCF from its reported cash flow
Insider trades
What the people running Elite Pharmaceuticals Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $8.6K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 19, 2026 | Dash Barry HDirector | Bought | 30,000 | $8.6K |
| January 9, 2026 | Plassche DouglasEVP Operations | Exercised options | 2,500,000 | $75K |
| October 2, 2025 | Plassche DouglasEVP Operations | Sold | 800,000 | $499.2K |
Who owns ELTP
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
Largest institutional holders
Insiders
2 insiders reported holding 12,765,555 shares in total, about $3.2M at the last price.
| Holder | Shares |
|---|---|
| Plassche DouglasEVP Operations | 9,500,000 |
| Dash Barry HDirector | 3,265,555 |
Questions about ELTP
What does Elite Pharmaceuticals Inc do?
Elite Pharmaceuticals Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker ELTP.
Is Elite Pharmaceuticals Inc profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $56.7M on revenue of $141M, a net margin of 40.2%.
How much revenue does Elite Pharmaceuticals Inc make?
Over the twelve months to June 30, 2026 Elite Pharmaceuticals Inc reported revenue of $141M. That is 33.7% more than a year earlier.
When did Elite Pharmaceuticals Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 10, 2026.
Similar companies
Compare ELTP with
Follow ELTP
Get an email when Elite Pharmaceuticals Inc files with the SEC: results, executive changes, material agreements and annual reports.
Follow ELTP: get an email when it filesWhere the numbers come from
Financial figures are the values Elite Pharmaceuticals Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.